These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
242 related articles for article (PubMed ID: 36937821)
1. An update on the use of conventional and biological disease-modifying anti-rheumatic drugs in hand osteoarthritis. Tenti S; Bruyère O; Cheleschi S; Reginster JY; Veronese N; Fioravanti A Ther Adv Musculoskelet Dis; 2023; 15():1759720X231158618. PubMed ID: 36937821 [TBL] [Abstract][Full Text] [Related]
2. Current Treatment Options for Osteoarthritis. Hermann W; Lambova S; Muller-Ladner U Curr Rheumatol Rev; 2018; 14(2):108-116. PubMed ID: 28875826 [TBL] [Abstract][Full Text] [Related]
3. Effect of disease-modifying anti-rheumatic drugs in osteoarthritis: A meta-analysis. Mathieu S; Tournadre A; Soubrier M; Sellam J Joint Bone Spine; 2022 Nov; 89(6):105444. PubMed ID: 35908643 [TBL] [Abstract][Full Text] [Related]
4. Biologics or tofacitinib for rheumatoid arthritis in incomplete responders to methotrexate or other traditional disease-modifying anti-rheumatic drugs: a systematic review and network meta-analysis. Singh JA; Hossain A; Tanjong Ghogomu E; Kotb A; Christensen R; Mudano AS; Maxwell LJ; Shah NP; Tugwell P; Wells GA Cochrane Database Syst Rev; 2016 May; 2016(5):CD012183. PubMed ID: 27175934 [TBL] [Abstract][Full Text] [Related]
5. Infection risk in patients undergoing treatment for inflammatory arthritis: non-biologics versus biologics. Chiu YM; Chen DY Expert Rev Clin Immunol; 2020 Feb; 16(2):207-228. PubMed ID: 31852268 [No Abstract] [Full Text] [Related]
6. Hydroxychloroquine in patients with inflammatory and erosive osteoarthritis of the hands (OA TREAT): study protocol for a randomized controlled trial. Detert J; Klaus P; Listing J; Höhne-Zimmer V; Braun T; Wassenberg S; Rau R; Buttgereit F; Burmester GR Trials; 2014 Oct; 15():412. PubMed ID: 25348033 [TBL] [Abstract][Full Text] [Related]
7. Safety of long-term use of four common conventional disease modifying anti-rheumatic drugs in rheumatoid arthritis. Kedia AK; Mohansundaram K; Goyal M; Ravindran V J R Coll Physicians Edinb; 2021 Sep; 51(3):237-245. PubMed ID: 34528610 [TBL] [Abstract][Full Text] [Related]
8. Biologics or tofacitinib for people with rheumatoid arthritis naive to methotrexate: a systematic review and network meta-analysis. Singh JA; Hossain A; Mudano AS; Tanjong Ghogomu E; Suarez-Almazor ME; Buchbinder R; Maxwell LJ; Tugwell P; Wells GA Cochrane Database Syst Rev; 2017 May; 5(5):CD012657. PubMed ID: 28481462 [TBL] [Abstract][Full Text] [Related]
9. Influence of biologic and conventional disease-modifying antirheumatic drugs on COVID-19 incidence among rheumatic patients during the first and second wave of the pandemic in Iran. Sahebari M; Mirfeizi Z; Shariati-Sarabi Z; Dadgar Moghadam M; Hashemzadeh K; Firoozabadi M Reumatologia; 2022; 60(4):231-241. PubMed ID: 36186839 [TBL] [Abstract][Full Text] [Related]
10. Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases. Rainsford KD; Parke AL; Clifford-Rashotte M; Kean WF Inflammopharmacology; 2015 Oct; 23(5):231-69. PubMed ID: 26246395 [TBL] [Abstract][Full Text] [Related]
12. Tumour necrosis factor inhibitors versus combination intensive therapy with conventional disease modifying anti-rheumatic drugs in established rheumatoid arthritis: TACIT non-inferiority randomised controlled trial. Scott DL; Ibrahim F; Farewell V; O'Keeffe AG; Walker D; Kelly C; Birrell F; Chakravarty K; Maddison P; Heslin M; Patel A; Kingsley GH BMJ; 2015 Mar; 350():h1046. PubMed ID: 25769495 [TBL] [Abstract][Full Text] [Related]
13. Enzyme-linked immunosorbent assays for monitoring TNF-alpha inhibitors and antibody levels in people with rheumatoid arthritis: a systematic review and economic evaluation. Tikhonova IA; Yang H; Bello S; Salmon A; Robinson S; Hemami MR; Dodman S; Kharechko A; Haigh RC; Jani M; McDonald TJ; Hoyle M Health Technol Assess; 2021 Feb; 25(8):1-248. PubMed ID: 33555998 [TBL] [Abstract][Full Text] [Related]
14. [Disease-modifying treatment for inflammatory rheumatism in sub-Saharan Africa: outcome at 6 months of 205 Senegalese patients with rheumatoid arthritis]. Ndongo S; Pouye A; Lekpa FK; Bihéhé DM; Tiendrebeogo J; Ndao AC; Ka MM; Moreira Diop T Med Sante Trop; 2012; 22(4):385-9. PubMed ID: 23352953 [TBL] [Abstract][Full Text] [Related]
15. Repurposing drugs for the treatment of osteoarthritis. Kuswanto W; Baker MC Osteoarthritis Cartilage; 2024 May; ():. PubMed ID: 38821468 [TBL] [Abstract][Full Text] [Related]
16. Cognitive impairment in elderly patients with rheumatic disease and the effect of disease-modifying anti-rheumatic drugs. Sood A; Raji MA Clin Rheumatol; 2021 Apr; 40(4):1221-1231. PubMed ID: 32862311 [TBL] [Abstract][Full Text] [Related]
17. Treatment of very early rheumatoid arthritis with symptomatic therapy, disease-modifying antirheumatic drugs, or biologic agents: a cost-effectiveness analysis. Finckh A; Bansback N; Marra CA; Anis AH; Michaud K; Lubin S; White M; Sizto S; Liang MH Ann Intern Med; 2009 Nov; 151(9):612-21. PubMed ID: 19884622 [TBL] [Abstract][Full Text] [Related]
18. Update on the Pathomechanism, Diagnosis, and Treatment Options for Rheumatoid Arthritis. Lin YJ; Anzaghe M; Schülke S Cells; 2020 Apr; 9(4):. PubMed ID: 32260219 [TBL] [Abstract][Full Text] [Related]